NCT01381055

Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis

Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 164 (actual)
• Sponsor: Paulo Roberto Lima Machado · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether pentoxifylline associated to pentavalent antimony has a higher cure rate than pentavalent antimony alone in the treatment of cutaneous leishmaniasis.

Conditions

• Cutaneous Leishmaniasis

Interventions

Type	Name	Description
DRUG	Pentoxifylline	Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
DRUG	Placebo	Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.

Timeline

• Start date: 2012-03-01
• Primary completion: 2015-01-01
• Completion: 2015-10-01
• First posted: 2011-06-27
• Last updated: 2017-01-26

Locations

1 site across 1 country: Brazil